Chronic discogenic lower back pain - Healing Genes

Chronic discogenic lower back pain

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

AMG0103 in Subjects With Chronic Discogenic Lumbar Back Pain

A Phase 1b, Multicenter, Double-blind, Randomized, Placebo-controlled, Single Ascending-Dose, Clinical Study Evaluating the Safety, Tolerability and Exploratory Efficacy of a Targeted Single Injection of an Intradiscal Nuclear Factor-κB Decoy Oligodeoxynucleotide (AMG0103) in Subjects With Chronic Discogenic Lumbar Back Pain

Phase 1b


Doctors at several coordinating centers in IL, FL, and CA seek patients with chronic lower back pain due to disc degeneration to test a treatment that reduces inflammation through a therapy that can reduce genetic expression of inflammation.

Study participants will receive a low, medium, or high dose of this investigatory treatment via an intradiscal (between the discs) injection, with half of the participants receiving a placebo injection. Over the next several months, the patient will be assessed for pain reduction and X-rayed for disc space improvement, along with some lab assessments and MRIs.


  • Have chronic lower back pain for at least 6 months that responded poorly to at least 3 months of medical care
  • Be between the ages of 18 to 75 years
  • Not be pregnant
  • Using birth control from the time of enrollment on this study and for one year after treatment.
  • No history of an endocrine or metabolic disorder that affects the spine (eg, Paget’s disease).


  1. Screening before the treatment, including lab tests and possibly MRI or X-ray.
  2. An intradiscal injection.
  3. Medical visits at 1 month and 6 months that will include pain assessment, ability assessment, X-ray, MRI, and lab and urine tests.


The medical centers conducting this study are

Keck Medicine of USC (Los Angeles, CA)

Contact: Lena Galian    323-442-5303    [email protected]

University of California (San Diego, CA)

Contact: Jesal Parekh    858-822-1288    [email protected]

Spine Institute of San Diego (San Diego, CA)

Contact: Erin Mears    770-365-2555    [email protected]

Florida Medical Pain Management (Saint Petersburg, FL)

Contact: Yulissa Peguero    727-548-6100 ext 280    [email protected]

Rush University Medical Center (Chicago, IL)

Contact: Susan Dvojack    312-942-6689    [email protected]


AnGes, Inc. International Clinical Development
[email protected]

Or go online:

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader